23 April 2025
: Case report 
Telitacicept and Tacrolimus Synergy in Managing Refractory Primary Membranous Nephropathy: Case Insights
Unusual or unexpected effect of treatment
Renwei Huang
EF 1, Yuhe Yin EF 1, Zewen Zhao EF 1, Xiaoying Dong BC 1, Chao Chen B 2, Haowen Lin BC 1,3, Yiming Tao BC 1, Siqi Peng BC 1, Sichun Wen BC 1, Bohou Li BC 1, Qiong Wu D 1, Sijia Li D 1, Ting Lin D 1, Hao Dai D 1, Feng Wen D 1, Zhuo Li D 1, Lixia Xu D 1, Jianchao Ma D 1*, Shuangxin Liu AG 1, Zhonglin Feng A 1
DOI: 10.12659/AJCR.946727
Am J Case Rep 2025; 26:e946727
Figure 2. Changes during drug treatment and clinical indicators. (A) The patient was treated with medication. (B) After the treatment, the patient showed reduced ACR and PCR results. His albumin level increased and serum creatinine was stable. (C) The patient’s PLA2Rab level decreased and IgG level increased. (D) Changes in white blood cell, lymphocyte, and neutrophil counts were observed during the therapy period. PCR – protein-to-creatinine ratio; ACR – albumin-to-creatinine ration; ALB – albumin; Scr – serum creatinine; PLA2Rab – phospholipase A2 receptor antibody; IgG – immunoglobulin G; WBC – white blood cell; NEUT – neutrophil; LYMPH – lymphocyte.